RAPID Pathway: Transforming Medicare Coverage for Breakthrough Devices

On April 23, 2026, the U.S. Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) launched the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. Designed to streamline processes, RAPID aims to reduce the delay between FDA authorization and Medicare national coverage from over a year to potentially two months for select Class II and Class III breakthrough devices. These are innovative devices identified by the FDA as providing enhanced treatment or diagnosis for severe or life-threatening health conditions.

The purpose of RAPID is to sync regulatory procedures, allowing evidence collected for FDA review to also back Medicare coverage decisions, thereby diminishing the current time lag. Traditionally, distinct evidence requirements for FDA clearance and Medicare coverage have prolonged the reimbursement process by over a year. Through RAPID, early collaboration between CMS and FDA during premarket stages is intended to foster a cohesive evidence generation process, shortening CMS timelines significantly.

Unlike former proposals, RAPID doesn't guarantee automatic Medicare coverage with FDA approval. Instead, it aligns CMS’s National Coverage Determination (NCD) process with FDA reviews to ensure a proposed NCD is released simultaneously with FDA authorization and finalized within 60 to 90 days. This determination remains contingent on a public comment period and CMS’s final judgment.

CMS has additionally suggested abolishing the New Technology Add-On Payment (NTAP) pathway for Breakthrough Devices as laid out in the FY 2027 Inpatient Prospective Payment System proposal. If implemented, this repeal would eliminate the add-on payments given without proven clinical enhancements, creating potential challenges for manufacturers needing to meet conventional criteria for payment.

FDA's Breakthrough Device program accelerates the review of devices offering advanced treatment or diagnosis for critical health conditions. However, FDA approval does not assure Medicare coverage, which requires CMS to assess medical necessity for coverage decisions, including NCDs that ensure national coverage, historically a lengthy and uncertain process.

RAPID differentiates itself by bridging the gap from the start of the Investigational Device Exemption phase, ensuring clinical trials produce evidence needed for both FDA and Medicare coverage determinations. This approach aims to prevent situations where post-FDA review, companies discover their evidence insufficient for Medicare coverage.

The RAPID pathway, compared to the previously paused TCET framework, shows significant enhancements, such as:

• Increased number of eligible devices.
• Enhanced coordination between FDA and CMS.
• A shortened timeline for finalizing coverage.

To qualify for RAPID, a device must be designated a Breakthrough Device, meet Medicare beneficiaries' unmet needs, and be involved in an IDE study with agreed-upon clinical outcomes from both FDA and CMS. CMS will suspend the TCET framework for new devices during RAPID’s implementation, with a call for public comments expected.

RAPID presents a notable movement in federal initiatives to align FDA authorization and Medicare coverage, potentially expediting Medicare access, which can influence private payer decisions favorably. This shift could also attract investors by shortening the timeline from investment to commercial viability. RAPID's extensive capacity compared to TCET signifies CMS’s aim to effectively influence the medical technology sector's growth. Nonetheless, previous limited successes in agency alignment underscore the importance of these initiatives’ detailed execution.

Additionally, CMS's proposal to repeal the NTAP mechanism aligns with efforts to optimize reimbursement structures, with implementation planned for FY 2028. The public commentary periods for both the RAPID procedural notice and NTAP pathway elimination will be critical for stakeholders. Effective execution of RAPID might reduce legislative pressure for automatic coverage under the Ensuring Patient Access to Critical Breakthrough Products Act, offering manufacturers a swifter administrative route at the potential expense of statutory coverage guarantees.

These developments could distinctly affect how CMS decides whether and how much to reimburse for breakthrough devices, influencing commercial adoption and market strategies. Investors should consider these regulatory adjustments as they might affect the economic landscape for breakthrough medical devices.